AASLD 2012 Advances in Chronic Hepatitis C Management and Treatment

  VE-AASLD-2012-Newsletter-Banner_v1.jpg

AASLD-2012_newsletter_button.jpg

About the Program

Program Overview

This CME newsletter will review and discuss the most important studies presented on chronic hepatitis C during the 63rd AASLD. This activity will enable all participating clinicians and health care providers caring for HCV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care.  

Back to Top  

Target Audience

This activity is intended for physicians, physician assistants, advanced practice nurses, and other health care professionals involved in the treatment and management of patients with HCV infection. 

Back to Top

Learning Objectives

After completing this activity, participants should be able to:

  • Review clinically relevant posters and presentations on chronic hepatitis C made at the 63rd AASLD; 

  • Explain to colleagues the clinical trials and data presented in the most important posters and presentations on chronic hepatitis C at the 63rd AASLD;

  • Explain the scientific integrity and clinical relevance of the most important posters and presentations on chronic hepatitis C at the 63rd AASLD;

  • Use the information and data presented in the most important posters and presentations at the 63rd AASLD to improve patient care.

Release Date: 
Expiration Date:

Estimated time to complete this CME Newsletter: 45 minutes 

Media: Internet

Back to Top

Faculty

Douglas T. Dieterich, MD
Professor of Medicine and Director of CME
Department of Medicine
Director of Outpatient Hepatology
Division of Liver Diseases
Mount Sinai School of Medicine
New York, New York

Paul Y. Kwo, MD
Professor of Medicine
Medical Director, Liver Transplantation
Division of Gastroenterology and Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Paul J. Pockros, MD 
Head, Division of Gastroenterology/Hepatology
Director, SC Liver Research Consortium
The Scripps Clinic
La Jolla, California 

Professor Jean-Michel Pawlotsky, MD, PhD
Director, National Reference Center for Viral Hepatitis B, C and Delta
Head, Department of Virology, Henri Mondor Hospital
University of Paris-Est and INSERM U955
Creteil, France

Back to Top  

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Postgraduate Institute for Medicine and ViralEd, Inc.. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.   

Back to Top

Credit Designation

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by the Postgraduate Institute for Medicine for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Dr. Douglas Dieterich:

  • Consulting Fees: BMS; Gilead; Genentech; Boehringer Ingelheim; Merck

Dr. Paul Kwo:

  • Contracted Research: Merck; Vertex; BMS; Abbott; Gilead; Idenix
  • Consulting Fees: Merck; Vertex; BMS; Abbott; Gilead; Anadys
  • Speakers' Bureau: Human Genome Sciences; Merck; Roche; BMS; Gilead; GlaxoSmithKline

Dr. Paul Pockros:

  • Contracted Research: Abbott; Tibotec; Pfizer; Contus; Novartis; 3RT; Gilead; Vertex; BMS
  • Consulting Fees: Gilead; Abbott; Tibotec; Pfizer; Contus; Novartis; 3RT
  • Advisory Boards: Vertex; Merck; BMS; Tibotec; Contus; Novartis; 3RT 
  • Spakers' Bureau: Vertex; Gilead; BMS

Professor Jean-Michel Pawlotsky, MD, PhD

  • Consulting Fees:Abbott; Achillion; Anadys; Biotics; Boehringer Ingelheim; BMS; Gen-Probe; Gilead; GlaxoSmithKline; Inhibitex; Janssen-Cilag; Madaus-Rottapharm; Sanofi-Aventis; Merck; Novartis; Pfizer; Roche
  • Contracted Research: Gilead; Roche

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Julia Kimball, RN, BSN; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine, ViralEd, Inc. and Merck & Co. do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Postgraduate Institute for Medicine, ViralEd, Inc. and Merck & Co. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Instructions for Participation and Credit

There are no fees for participating and receiving credit for this activity. During the period, Date December 3, 2012 through December 3, 2013, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and evaluation form.

To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on the Submit Post-test at the bottom of the page. Your post-test will automatically be graded.

If you successfully complete the post-test (score of 70% or higher). your certificate will be made available immediately. Click on View Certificate and print the certificate for your records. If you received a score of 69% or less, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful.

You may complete the Post-test on-line at www.cmeuniversity.com

  • Click on "Find Post-Test/Evaluation by Course" on the navigation menu
  • Search by project ID: 8926
  • Upon successfully completing the Post-test and Evaluation form, your certificate will be made available immediately.

Back to Top

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.   

Back to Top

PIM_small

  Jointly Sponsored by the Postgraduate Institute for Medicine and ViralEd, Inc..

Supported by an educational grant from Merck & Co., Inc.

*This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings


Prepare to print

Share this page:

Get link code to this page     


Back to Top